Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review

References

• Global Hepatitis Report. [Internet]. Geneva: World Health Organization; 2017. [2018 May, 29]. Available from: http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1.
   Google Scholar
• GBD. 2016 Disease and injury incidence and prevalence collaborators. global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the global burden disease study 2016. NEJM. 2017;390:1211–1259.
   Google Scholar
• GBD 2016 Mortality Collaborators. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the global burden of disease study 2016. NEJM. 2017;390:1084–1150.
   Google Scholar
• Chhatwal J, He T, Lopez-Olivo MA. Systematic review of modeling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antivirals. Pharmacoeconomics. 2016;34(6):551–567.
   PubMed Web of Science ®Google Scholar
• Jakobsen JC, Nielsen EE, Feinberg J, et al. Direct-acting antivirals for chronic hepatitis C (Review). Cochrane Database of Sys Rev. 2017;9:1–751.
   Google Scholar
• Younossi ZM, Park H, Dieterich D, et al. Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: the quality-adjusted cost of care. Medicine. 2016;95(41):e5048.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Sanders GD, Russell LB, et al. Cost-effectiveness in health and medicine. 2nd ed. New York: Oxford University Press; 2017.
   Google Scholar
• Bickerstaff C. The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C. Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):787–800.
   PubMed Web of Science ®Google Scholar
• Luhnen M, Waffenschmidt S, Gerber-Grote A, et al. Health economic evaluation of Sofosbuvir for treatment of chronic hepatitis C: a systematic review. Appl Health Econ Health Policy. 2016;14:527–543.
   PubMed Web of Science ®Google Scholar
• Chhatwal J, He T, Hur C, et al. Direct-acting antiviral agents for patients with hepatitis C virus genotype 1 infection are cost saving. Clin Gastroenterol Hepatol. 2017;15:827–837.
   PubMed Web of Science ®Google Scholar
• He T, Lopez-Olivo MA, Hur C. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2–6. Aliment Pharmacol Ther. 2017;46:711–721.
   PubMed Web of Science ®Google Scholar
• Caro J, Briggs AH, Siebert U, et al. Modeling good research practices –overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value Health. 2012;15(6):796–803.
   PubMed Web of Science ®Google Scholar
• GDP Deflator. [Internet] World Bank national accounts data, and OECD national accounts data files; The World Bank Data. [ cited 2018 May 29]. Available from: http://data.worldbank.org/indicator/NY.GDP.DEFL.ZS. [2018 May 23].
   Google Scholar
• Current and historical rate tables [Internet]. XE; updated 2018 May 23; [cited 2018 May 29]. Available from: http://www.xe.com/currencytables/
   Google Scholar
• Alavian SM, Nikfar S, Kebriaeezadeh A, et al. A cost-utility analysis of different antiviral medicine regimens in patients with chronic hepatitis C virus genotype 1 infection. Iranian Red Crescent Med J. 2016;18(11):e37094.
   PubMed Web of Science ®Google Scholar
• Arshad M, Wei F, Nelsen JDA, et al. disease and its management: a cost-effectiveness analysis of the new generation oral protease inhibitors. Antivir Therap. 2015;20(8):827–833.
   PubMed Web of Science ®Google Scholar
• Chen G-F, Wei L, Chen J, et al. Will sofosbuvir/ledipasvir (Harvoni) be cost-effective and affordable for chinese patients infected with hepatitis C virus? An economic analysis using real-world data. Plos One. 2016;11(6):e0155934.
   PubMed Web of Science ®Google Scholar
• Chhatwal J, Kanwal F, Roberts MS, et al. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015;162(6):397–406.
   PubMed Web of Science ®Google Scholar
• Cure S, Guerra I, Dusheiko G. Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients. J Viral Hepat. 2015;22(11):882–889.
   PubMed Web of Science ®Google Scholar
• Cure S, Guerra I, Cammà C, et al. Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy. J Med Econ. 2015;18(9):678–690.
   PubMed Web of Science ®Google Scholar
• Fraser I, Burger J, Lubbe M, et al. Cost-effectiveness modeling of sofosbuvir-containing regimens for chronic genotype 5 hepatitis C virus infection in South Africa. PharmacoEconomics. 2016;34(4):403–417.
   PubMed Web of Science ®Google Scholar
• Gimeno-Ballester V, Mar J, O’Leary A, et al. Cost-effectiveness analysis of therapeutic options for hepatitis C genotype 3 infected patients. Expert Rev Gastroenterol Hepatol. 2016;11:85–93.
   Web of Science ®Google Scholar
• Gimeno-Ballester V, Mar J, Miguel RS. Cost–effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C. Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):285–294.
   PubMed Web of Science ®Google Scholar
• Gissel C, Götz G, Mahlich J, et al. Cost-effectiveness of Interferon-free therapy for hepatitis C in Germany - an application of the efficiency frontier approach. BMC Infect Dis. 2015;15(1):297.
   PubMed Web of Science ®Google Scholar
• Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology. 2014;60(1):37–45.
   PubMed Web of Science ®Google Scholar
• Johnson SJ, Parisé H, Virabhak S, et al. Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection. J Med Econ. 2016;19(10):983–994.
   PubMed Web of Science ®Google Scholar
• Kuwabara H, Westerhout K, Treur M, et al. Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan. J Med Econ. 2015;18(7):502–511.
   PubMed Web of Science ®Google Scholar
• Leleu H, Blachier M, Rosa I. Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. J Viral Hepat. 2015;22:376–383.
   PubMed Web of Science ®Google Scholar
• Linas BP, Barter DM, Morgan JR, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Inter Med. 2015;162(9):619–629.
   PubMed Web of Science ®Google Scholar
• McEwan P, Ward T, Webster S, et al. Estimating the long-term clinical and economic outcomes of daclatasvir plus asunaprevir in difficult-to-treat Japanese patients chronically infected with hepatitis C Genotype 1b. Value Health Reg Issues. 2014;3:136–145.
   PubMedGoogle Scholar
• McEwan P, Bennett H, Ward T, et al. The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK. Eur J Gastroenterol Hepatol. 2016;28:173–180.
   PubMed Web of Science ®Google Scholar
• McEwan P, Ward T, Webster S, et al. Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. Hepatol Res. 2016;46(5):423–433.
   PubMed Web of Science ®Google Scholar
• Moshyk A, Martel M-J, Monfared AAT, et al. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada. J Med Econ. 2016;19(2):191–202.
   PubMed Web of Science ®Google Scholar
• Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Inter Med. 2015;162(6):407–419.
   PubMed Web of Science ®Google Scholar
• Ollendorf DA, Tice JA, Pearson SD. The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection. JAMA Inter Med. 2014;174(7):1170.
   PubMed Web of Science ®Google Scholar
• Petta S, Cabibbo G, Enea M, et al. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatol. 2014;59(5):1692–1705.
   PubMed Web of Science ®Google Scholar
• Pfeil AM, Reich O, Guerra IM, et al. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C. Plos One. 2015;10(5):e0126984.
   PubMed Web of Science ®Google Scholar
• Rein DB, Wittenborn JS, Smith BD, et al. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Cid. 2015;61:157–168.
   PubMed Web of Science ®Google Scholar
• Saab S, Gordon SC, Park H, et al. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2014;40(6):657–675.
   PubMed Web of Science ®Google Scholar
• Saab S, Parisé H, Virabhak S, et al. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. J Med Econ. 2016;19(8):795–805.
   PubMed Web of Science ®Google Scholar
• San Miguel RCB, Gimeno-Ballester V, Blázquez A, et al. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut. 2015;64(8):1277–1288.
   PubMed Web of Science ®Google Scholar
• Stahmeyer JT, Rossol S, Liersch S, et al. Cost-effectiveness of treating hepatitis C with sofosbuvir/ledipasvir in Germany. Plos One. 2017;12(1):e0169401.
   PubMed Web of Science ®Google Scholar
• Vargas CL, Espinoza MA, Giglio A, et al. Cost effectiveness of daclatasvir/asunaprevir versus peginterferon/ribavirin and protease inhibitors for the treatment of hepatitis C Genotype 1b naïve patients in Chile. Plos One. 2015;10(11):e0141660.
   PubMed Web of Science ®Google Scholar
• Westerhout K, Treur M, Mehnert A, et al. A cost utility analysis of simeprevir used with peginterferon ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service. J Med Econ. 2015;18(10):838–849.
   PubMed Web of Science ®Google Scholar
• Wong WWL, Lee KM, Singh S, et al. Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis. CMAJ Open. 2017;5(1):E97–E108.
   PubMedGoogle Scholar
• Younossi ZM, Park H, Saab S, et al. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015;41(6):544–563.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Park H, Dieterich D, et al. Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States. Medicine. 2016;95(41):e5048.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Park H, Dieterich D, et al. The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: are the new all-oral regimens good value to society? Liver Int. 2016;37(5):662–668.
   PubMed Web of Science ®Google Scholar
• Zhang S, Bastian ND, Griffin PM. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. BMC Gastroenterol. 2015;15:98.
   PubMed Web of Science ®Google Scholar
• Zhao YJ, Khoo AL, Lin L, et al. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C. J Gastroenterol Hepatol. 2016;31(9):1628–1637.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. The PRISMA group. preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Basu A. Estimating costs and valuations on non-health benefits in cost-effectiveness analysis. In: Neumann PJ, Sanders GD, Russell LB, et al., editors. Cost-Effectiveness in Health and Medicine. 2nd ed. Oxford: Oxford University Press; 2017. p. 210–236.
   Google Scholar
• Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economics evaluation of health care programmes. 4th ed. Oxford: Oxford Univertity Press; 2015.
   Google Scholar
• Pascual-Argenté N, Puig-Junoy J, Llagostera-Punzano A. Non-healthcare costs of hepatitis C: a systematic review. Expert Rev Gastroenterol Hepatol. 2018;12(1):19–30.
   PubMed Web of Science ®Google Scholar
• Vellopoulou A, van Agthoven M, van der Kolk A, et al. Cost utility of telaprevir-PR (peginterferon-ribavirin) versus boceprevir-PR and versus PR alone in chronic hepatitis C in the Netherlands. Appl Health Econ Health Policy. 2014;12:647–659.
   PubMedGoogle Scholar
• Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force-7. Med Decis Making, 2012; 32: 733–743.
   PubMed Web of Science ®Google Scholar
• Gray AM, Clarke PM, Wolstenholme JL, et al. Applied methods of cost-effectiveness analysis in health care. series: handbooks in health economic evaluation series. Oxford: Oxford University Press; 2010.
   Google Scholar
• Lakdawalla D, McEwan JP, Dubois R, et al. What do pharmaceuticals really cost in the long run. Am J Manag Care. 2017;23:488–493.
   PubMed Web of Science ®Google Scholar